Bessemer Group Inc. lifted its holdings in shares of LeMaitre Vascular Inc (NASDAQ:LMAT) by 45.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 30,500 shares of the medical instruments supplier’s stock after buying an additional 9,500 shares during the period. Bessemer Group Inc.’s holdings in LeMaitre Vascular were worth $721,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. BlackRock Inc. increased its holdings in LeMaitre Vascular by 2.2% in the 4th quarter. BlackRock Inc. now owns 2,601,309 shares of the medical instruments supplier’s stock worth $61,496,000 after purchasing an additional 56,161 shares in the last quarter. Conestoga Capital Advisors LLC increased its holdings in LeMaitre Vascular by 4.1% in the 4th quarter. Conestoga Capital Advisors LLC now owns 1,673,131 shares of the medical instruments supplier’s stock worth $39,553,000 after purchasing an additional 66,131 shares in the last quarter. Vanguard Group Inc. increased its holdings in LeMaitre Vascular by 5.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,208,742 shares of the medical instruments supplier’s stock worth $46,826,000 after purchasing an additional 66,427 shares in the last quarter. Vanguard Group Inc increased its holdings in LeMaitre Vascular by 5.8% in the 3rd quarter. Vanguard Group Inc now owns 1,208,742 shares of the medical instruments supplier’s stock worth $46,826,000 after purchasing an additional 66,427 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in LeMaitre Vascular by 1.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,020,116 shares of the medical instruments supplier’s stock worth $39,519,000 after purchasing an additional 14,038 shares in the last quarter. 76.71% of the stock is owned by institutional investors.

In other news, insider Trent G. Kamke sold 16,604 shares of the stock in a transaction dated Friday, February 22nd. The stock was sold at an average price of $29.63, for a total value of $491,976.52. Following the completion of the sale, the insider now owns 19,857 shares of the company’s stock, valued at $588,362.91. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 20.30% of the company’s stock.

Shares of LMAT stock opened at $31.27 on Friday. The stock has a market capitalization of $588.62 million, a PE ratio of 37.23, a P/E/G ratio of 2.98 and a beta of 1.15. LeMaitre Vascular Inc has a 1-year low of $21.79 and a 1-year high of $41.28.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Tuesday, February 19th. The medical instruments supplier reported $0.24 earnings per share for the quarter, meeting the consensus estimate of $0.24. The company had revenue of $28.39 million during the quarter, compared to analysts’ expectations of $26.06 million. LeMaitre Vascular had a return on equity of 17.71% and a net margin of 21.73%. Sell-side analysts expect that LeMaitre Vascular Inc will post 0.84 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, April 5th. Stockholders of record on Friday, March 22nd will be paid a $0.085 dividend. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.07. The ex-dividend date of this dividend is Thursday, March 21st. This represents a $0.34 annualized dividend and a dividend yield of 1.09%. LeMaitre Vascular’s dividend payout ratio is presently 33.33%.

A number of brokerages have issued reports on LMAT. ValuEngine raised LeMaitre Vascular from a “sell” rating to a “hold” rating in a report on Wednesday, February 20th. BidaskClub raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Roth Capital reaffirmed a “neutral” rating on shares of LeMaitre Vascular in a report on Thursday, February 21st. Zacks Investment Research cut LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Thursday, December 6th. Finally, Lake Street Capital upped their target price on LeMaitre Vascular to $27.00 and gave the stock a “hold” rating in a report on Wednesday, February 20th. One analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $33.29.

WARNING: “LeMaitre Vascular Inc (LMAT) Shares Bought by Bessemer Group Inc.” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/lemaitre-vascular-inc-lmat-shares-bought-by-bessemer-group-inc/2896295.html.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Featured Article: What are the FAANG Stocks?

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.